Epigallocatechin Gallate → Hesperidin
Reaktionsgleichung
[CH3:1][C@@H:2]1[O:7][C@@H:6]([O:8][CH2:9][C@H:10]2[O:15][C@@H:14]([O:16][C:17]3[CH:27]=[C:26]4[C:20]([C:21]([CH2:23][C@@H:24]([C:28]5[CH:33]=[CH:32][C:31]([O:34][CH3:35])=[C:30]([O:36][CH3:37])[CH:29]=5)[O:25]4)=[O:22])=[C:19]([OH:38])[CH:18]=3)[C@@H:13]([OH:39])[C@@H:12]([OH:40])[C@@H:11]2[OH:41])[C@H:5]([OH:42])[C@H:4]([OH:43])[C@H:3]1[OH:44].C1C2C(=CC(O)=CC=2O)O[C@H](C2C=C(O)C(O)=C(O)C=2)[C@@H]1OC(C1C=C(O)C(O)=C(O)C=1)=O>>[CH3:1][C@@H:2]1[O:7][C@@H:6]([O:8][CH2:9][C@H:10]2[O:15][C@@H:14]([O:16][C:17]3[CH:18]=[C:19]([OH:38])[C:20]4[C:21](=[O:22])[CH2:23][C@@H:24]([C:28]5[CH:33]=[CH:32][C:31]([O:34][CH3:35])=[C:30]([OH:36])[CH:29]=5)[O:25][C:26]=4[CH:27]=3)[C@H:13]([OH:39])[C@@H:12]([OH:40])[C@@H:11]2[OH:41])[C@H:5]([OH:42])[C@H:4]([OH:43])[C@H:3]1[OH:44].[CH3:1][C@@H:2]1[O:7][C@@H:6]([O:8][CH2:9][C@H:10]2[O:15][C@@H:14]([O:16][C:17]3[CH:27]=[C:26]4[C:20]([C:21]([CH2:23][C@@H:24]([C:28]5[CH:33]=[CH:32][C:31]([O:34][CH3:35])=[C:30]([O:36][CH3:37])[CH:29]=5)[O:25]4)=[O:22])=[C:19]([OH:38])[CH:18]=3)[C@@H:13]([OH:39])[C@@H:12]([OH:40])[C@@H:11]2[OH:41])[C@H:5]([OH:42])[C@H:4]([OH:43])[C@H:3]1[OH:44]Komponenten
4
Edukt 2
Produkt 2
Versuchsvorschrift
A hesperidin composition was obtained as a hesperidin-containing aqueous solution by a same procedure as in Example 1, except that a methylhesperidin preparation (manufactured by Hamari Chemicals Ltd., methylhesperidin content 100%, the same shall apply hereafter) was used instead of the EGCG preparation. Reaction conditions and the measurement result of a concentration of hesperidin and methylhesperidin in the composition are shown in Table 1.
Aufarbeitung
- additioncontaining aqueous solution by a same procedure as in Example 1
- customReaction conditions
Quellen und Nachweise
- ORD-Eintrag
- ord-e800ded5b7514afcbd1973e8261151bb
- Quelldatensatz
- uspto-grants-2015_07
- Patentnummer
- US09079933B2
Notizen zur Reaktion
Wird geladen…